Fatty acid binding protein 5 promotes metastatic potential of triple negative breast cancer cells through enhancing epidermal growth factor receptor stability
暂无分享,去创建一个
Charles Shapiro | C. Shapiro | K. Shilo | R. Ganju | M. Nasser | Mohd W. Nasser | Catherine A. Powell | Helong Zhao | Jacob C. Wochna | Xiaoli Zhang | Konstantin Shilo | Ramesh K. Ganju | Xiaoli Zhang | C. Powell | Helong Zhao
[1] H. Leffers,et al. Molecular cloning and expression of a novel keratinocyte protein (psoriasis-associated fatty acid-binding protein [PA-FABP]) that is highly up-regulated in psoriatic skin and that shares similarity to fatty acid-binding proteins. , 1992, The Journal of investigative dermatology.
[2] T. Ono,et al. Identification of the messenger RNA for human cutaneous fatty acid-binding protein as a metastasis inducer. , 2000, Cancer research.
[3] P. Rudland,et al. Human cutaneous fatty acid-binding protein induces metastasis by up-regulating the expression of vascular endothelial growth factor gene in rat Rama 37 model cells. , 2001, Cancer research.
[4] R. Parker,et al. Role of the fatty acid binding protein mal1 in obesity and insulin resistance. , 2003, Diabetes.
[5] C. Shi,et al. Pyk2 Amplifies Epidermal Growth Factor and c-Src-induced Stat3 Activation* , 2004, Journal of Biological Chemistry.
[6] M. J. Ehrke,et al. Distant metastasis from subcutaneously grown E0771 medullary breast adenocarcinoma. , 2005, Anticancer research.
[7] L. Makowski,et al. The role of fatty acid binding proteins in metabolic syndrome and atherosclerosis , 2005, Current opinion in lipidology.
[8] J. Quigley,et al. Matrix metalloproteinases and tumor metastasis , 2006, Cancer and Metastasis Reviews.
[9] S. Narod,et al. Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.
[10] Erik Sahai,et al. Illuminating the metastatic process , 2007, Nature Reviews Cancer.
[11] W. Travis,et al. Alpha-methylacyl CoA racemase in pulmonary adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumors: expression and survival analysis. , 2007, Archives of pathology & laboratory medicine.
[12] M. Furuhashi,et al. Adipocyte/macrophage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice. , 2008, The Journal of clinical investigation.
[13] M. Furuhashi,et al. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets , 2008, Nature Reviews Drug Discovery.
[14] A. Tutt,et al. Triple negative tumours: a critical review , 2007, Histopathology.
[15] G. Tuszynski,et al. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis , 2009, Pathology Oncology Research.
[16] M. Clynes,et al. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] J. Suttles,et al. Regulation of Th17 Differentiation by Epidermal Fatty Acid-Binding Protein1 , 2009, The Journal of Immunology.
[18] Z. Szallasi,et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients , 2010, Breast Cancer Research and Treatment.
[19] C. Lipinski,et al. Targeting Pyk2 for therapeutic intervention , 2010, Expert opinion on therapeutic targets.
[20] Jorge S Reis-Filho,et al. Triple-negative breast cancer. , 2010, The New England journal of medicine.
[21] C. Morrison,et al. Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features , 2011, Breast Cancer Research and Treatment.
[22] W. Chiang,et al. Fatty-acid-binding protein 5 promotes cell proliferation and invasion in oral squamous cell carcinoma. , 2009, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.
[23] Padmamalini Kannan-Thulasiraman,et al. Involvement of Fatty Acid Binding Protein 5 and PPARβ/δ in Prostate Cancer Cell Growth , 2010, PPAR research.
[24] Stephanie Alexander,et al. Cancer Invasion and the Microenvironment: Plasticity and Reciprocity , 2011, Cell.
[25] Padmamalini Kannan-Thulasiraman,et al. Fatty acid-binding protein 5 and PPARβ/δ are critical mediators of epidermal growth factor receptor-induced carcinoma cell growth. , 2011, The Journal of Biological Chemistry.
[26] J. Mackey,et al. Association of FABP5 expression with poor survival in triple-negative breast cancer: implication for retinoic acid therapy. , 2011, The American journal of pathology.
[27] Tao Qin,et al. EGFR expression correlates with decreased disease-free survival in triple-negative breast cancer: a retrospective analysis based on a tissue microarray , 2012, Medical Oncology.
[28] M. Linton,et al. Macrophage Mal1 Deficiency Suppresses Atherosclerosis in Low-Density Lipoprotein Receptor–Null Mice by Activating Peroxisome Proliferator-Activated Receptor-&ggr;–Regulated Genes , 2011, Arteriosclerosis, thrombosis, and vascular biology.
[29] S. Borstnar,et al. Triple negative breast cancer – prognostic factors and survival , 2010, Radiology and oncology.
[30] E. Rakha,et al. Metastatic triple-negative breast cancer. , 2011, Clinical oncology (Royal College of Radiologists (Great Britain)).
[31] K. Gelmon,et al. Targeting triple-negative breast cancer: optimising therapeutic outcomes. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[32] R. Okuyama,et al. Epidermal-type FABP is a predictive marker of clinical response to systemic treatment and ultraviolet therapy in psoriatic skin lesions. , 2012, Journal of dermatological science.
[33] Hiroko Masuda,et al. Role of epidermal growth factor receptor in breast cancer , 2012, Breast Cancer Research and Treatment.
[34] K. Shilo,et al. S100A7 enhances mammary tumorigenesis through upregulation of inflammatory pathways. , 2011, Cancer research.
[35] Gregory P Tochtrop,et al. Genetic ablation of the fatty acid-binding protein FABP5 suppresses HER2-induced mammary tumorigenesis. , 2013, Cancer research.
[36] K. Imai,et al. Comprehensive fluorogenic derivatization-liquid chromatography/tandem mass spectrometry proteomic analysis of colorectal cancer cell to identify biomarker candidate. , 2013, Biomedical chromatography : BMC.
[37] R. Greil,et al. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] K. Shilo,et al. FAAH inhibition enhances anandamide mediated anti-tumorigenic effects in non-small cell lung cancer by downregulating the EGF/EGFR pathway , 2014, Oncotarget.
[39] J. Iovanna,et al. Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations , 2014, British Journal of Cancer.
[40] B. Yadav,et al. Systemic treatment strategies for triple-negative breast cancer. , 2014, World journal of clinical oncology.